

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in





Anti-Nerve growth factor [mab 911] Standard Size Ab03301-10.3

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format for improved compatibility with existing reagents assays and techniques.

Isotype and Format: Human IgG1, Fc Silent™, Kappa

Clone Number: mab 911

Alternative Name(s) of Target: Beta-nerve growth factor; Beta-NGF

UniProt Accession Number of Target Protein: P01138

Published Application(s): Blocking, crystallization, in vitro, in vivo, inhibition, therapeutic, ELISA

Published Species Reactivity: Human, Mouse

Immunogen:

Specificity: The antibody is specific for NGF. The NGF epitope is composed of β -strand segments from both NGF monomers. NGF is involved primarily in the growth, as well as the maintenance, proliferation, and survival of nerve cells (neurons).

Application Notes: The specificity of the original format of the antibody to NGF was confirmed by ELISA analysis (EC50 = 0.37 nM). The antibody was evaluated for its ability to block the binding of hNGF to the TrkA and p75 NGF receptors in various in vitro assays, such as blocking of TrkA autophosphorylation and blocking of NGF-dependent survival of dorsal root ganglion sensory neurons. The antibody was a potent blocker of all activities (Hongo et al., 2000; PMID: 10952410). In vivo administration of the antibody significantly reduces bone cancer pain behaviors (Sevcik et al., 2005; PMID: 15836976 and Halvorson et al., 2005; PMID: 16230406 and Buehlmann et al., 2019; PMID: 30161041) and fracture pain-related behaviors (Koewler et al., 2007; PMID: 17638576). The structure of Nerve Growth factor in complex with the Fab fragment was determined. Library Scanning Mutagenesis method was used to convert the original antibody in the humanized antibody tanezumab. The antibody bound human and murine NGF with high affinity (KD ~10 nM). Tanezumab and the original antibody blocked both TrkA and p75NTR binding to NGF and inhibited NGF-dependent neuron survival. Tanezumab inhibited NGFdependent survival with an IC50 of 15 pM; under the same conditions, 911 inhibited NGF with an IC50 of 400 pM (La Porte et al., 2014; PMID: 24830649). Preventative and therapeutic treatment with the antibody significantly prevented, or reversed, MIA-induced

pain behaviour in osteoarthritis (Xu et al., 2016; PMID: 27208420).

Antibody First Published in: Hongo et al. Antibody binding regions on human nerve growth factor identified by homolog- and alanine-scanning mutagenesis. Hybridoma. 2000 Jun;19(3):215-27. PMID:10952410

Note on publication: The original paper describes the generation and characterization of a panel of monoclonal antibodies.

Product Form

Size: 200 μg Purified antibody.

Purification: Protein A affinity purified **Supplied In:** PBS with 0.02% Proclin 300.

Storage Recommendation: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -

20°C.

Concentration: 1 mg/ml.

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.